作者
Samantha M Morrissey, Anne E Geller, Xiaoling Hu, David Tieri, Chuanlin Ding, Christopher K Klaes, Elizabeth A Cooke, Matthew R Woeste, Zachary C Martin, Oscar Chen, Sarah E Bush, Huang-ge Zhang, Rodrigo Cavallazzi, Sean P Clifford, James Chen, Smita Ghare, Shirish S Barve, Lu Cai, Maiying Kong, Eric C Rouchka, Kenneth R McLeish, Silvia M Uriarte, Corey T Watson, Jiapeng Huang, Jun Yan
发表日期
2021/5/10
期刊
JCI insight
卷号
6
期号
9
出版商
American Society for Clinical Investigation
简介
SARS coronavirus 2 (SARS-CoV-2) is a novel viral pathogen that causes a clinical disease called coronavirus disease 2019 (COVID-19). Although most COVID-19 cases are asymptomatic or involve mild upper respiratory tract symptoms, a significant number of patients develop severe or critical disease. Patients with severe COVID-19 commonly present with viral pneumonia that may progress to life-threatening acute respiratory distress syndrome (ARDS). Patients with COVID-19 are also predisposed to venous and arterial thromboses that are associated with a poorer prognosis. The present study identified the emergence of a low-density inflammatory neutrophil (LDN) population expressing intermediate levels of CD16 (CD16 Int) in patients with COVID-19. These cells demonstrated proinflammatory gene signatures, activated platelets, spontaneously formed neutrophil extracellular traps, and enhanced …
学术搜索中的文章
SM Morrissey, AE Geller, X Hu, D Tieri, C Ding… - JCI insight, 2021